189 related articles for article (PubMed ID: 28731125)
1. N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.
Wang Y; Wang H; Ding Y; Li Y; Chen S; Zhang L; Wu H; Zhou J; Duan K; Wang W; Chen C; Yang Q
Int J Oncol; 2017 Sep; 51(3):918-930. PubMed ID: 28731125
[TBL] [Abstract][Full Text] [Related]
2. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
[TBL] [Abstract][Full Text] [Related]
3. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ
Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580
[TBL] [Abstract][Full Text] [Related]
4. Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Wang W; Zhang L; Wang Y; Ding Y; Chen T; Wang Y; Wang H; Li Y; Duan K; Chen S; Yang Q; Chen C
Cell Death Dis; 2017 Oct; 8(10):e3071. PubMed ID: 28981108
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
[TBL] [Abstract][Full Text] [Related]
6. [Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells].
Zhao ZL; Cai Y; Wang YY; Xia CL; Li CX; Chen SL; Yang QL; Chen CJ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 44(4):400-9. PubMed ID: 26555418
[TBL] [Abstract][Full Text] [Related]
7. Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer.
Yang Q; Zhang F; Ding Y; Huang J; Chen S; Wu Q; Wang Z; Wang Z; Chen C
Br J Cancer; 2014 Mar; 110(5):1288-97. PubMed ID: 24448360
[TBL] [Abstract][Full Text] [Related]
8. [miR-16-5p regulates apoptosis and migration of drug-resistant breast cancer cells by targeting YWHAQ].
Zhu H; Mao H; Tao S; Wang W; Chen C; Yang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Oct; 42(10):1476-1485. PubMed ID: 36329581
[TBL] [Abstract][Full Text] [Related]
9. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
Yang Q; Wang Y; Lu X; Zhao Z; Zhu L; Chen S; Wu Q; Chen C; Wang Z
Oncotarget; 2015 Feb; 6(5):3268-79. PubMed ID: 25605244
[TBL] [Abstract][Full Text] [Related]
10. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR‑200c‑3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.
Chen J; Tian W; He H; Chen F; Huang J; Wang X; Chen Z
Oncol Rep; 2018 Dec; 40(6):3821-3829. PubMed ID: 30272330
[TBL] [Abstract][Full Text] [Related]
12. miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway.
Song L; Liu D; Wang B; He J; Zhang S; Dai Z; Ma X; Wang X
Oncol Rep; 2015 Jul; 34(1):525-31. PubMed ID: 25955111
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway.
Chen Y; Li X; Xu J; Xiao H; Tang C; Liang W; Zhu X; Fang Y; Wang H; Shi J
Bioengineered; 2022 Feb; 13(2):3526-3536. PubMed ID: 35200072
[TBL] [Abstract][Full Text] [Related]
14. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
15. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA‑335 inhibits bladder cancer cell growth and migration by targeting mitogen‑activated protein kinase 1.
Wang X; Wu G; Cao G; Chen X; Huang J; Jiang X; Hou J
Mol Med Rep; 2016 Aug; 14(2):1765-70. PubMed ID: 27356628
[TBL] [Abstract][Full Text] [Related]
17. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
18. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
20. The N-terminal polypeptide derived from vMIP-II exerts its antitumor activity in human breast cancer through CXCR4/miR-7-5p/Skp2 pathway.
Wang HF; Dong ZY; Yan L; Yang S; Xu HN; Chen SL; Wang WR; Yang QL; Chen CJ
J Cell Physiol; 2020 Dec; 235(12):9474-9486. PubMed ID: 32372405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
